Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IMGN

ImmunoGen (IMGN) Stock Price, News & Analysis

ImmunoGen logo

About ImmunoGen Stock (NASDAQ:IMGN)

Key Stats

Today's Range
$31.23
$31.23
50-Day Range
$31.23
$31.23
52-Week Range
$3.61
$31.25
Volume
40 shs
Average Volume
8.78 million shs
Market Capitalization
$8.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Artisan International Small-Mid Instl
Artisan International Small-Mid Advisor
Polaris Global Equity Composite Q1 2024 Commentary
3 Potential Biopharma Buyout Targets
See More Headlines

IMGN Stock Analysis - Frequently Asked Questions

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.14. The firm's quarterly revenue was up 485.9% compared to the same quarter last year.

ImmunoGen subsidiaries include these companies: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), General Electric (GE), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
7/31/2023
Today
12/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
277
Year Founded
1981

Profitability

Net Income
$-222,930,000.00
Pretax Margin
-25.24%

Debt

Sales & Book Value

Annual Sales
$287.61 million
Book Value
$0.71 per share

Miscellaneous

Free Float
252,764,000
Market Cap
$8.32 billion
Optionable
Optionable
Beta
1.18

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:IMGN) was last updated on 12/10/2024 by MarketBeat.com Staff
From Our Partners